Oral baclofen in children with cerebral palsy: a double-blind cross-over pilot study

J Paediatr Child Health. 2006 Nov;42(11):715-20. doi: 10.1111/j.1440-1754.2006.00957.x.

Abstract

Aim: To assess the effectiveness of oral baclofen in reducing spasticity and improving function in children with cerebral palsy.

Methods: A double-blind, randomised cross-over pilot study of oral baclofen versus placebo. Assessment tools included the Goal Attainment Scale, Pediatric Evaluation of Disability Inventory, Modified Tardieu Scale and parent questionnaire.

Results: Fifteen children with mean age 7.4 years (SD=2.7 years) and spastic or spastic/dystonic quadriplegia (Gross Motor Function Classification System Level IV or V) were enrolled. Children scored significantly better on the Goal Attainment Scale with baclofen compared with placebo (F(1,13)=4.5, P=0.05). There was no significant difference between baclofen and placebo for the Pediatric Evaluation of Disability Inventory or Modified Tardieu Scale. Parent questionnaire results are described.

Conclusion: This pilot study demonstrates that oral baclofen has an effect beyond placebo in improving goal-oriented tasks, such as transfers, in children with spastic quadriplegic cerebral palsy.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Baclofen / administration & dosage*
  • Cerebral Palsy / complications*
  • Child
  • Child, Preschool
  • Double-Blind Method
  • Humans
  • Muscle Spasticity / drug therapy*
  • Muscle Spasticity / prevention & control
  • New Zealand
  • Pilot Projects
  • Placebos

Substances

  • Placebos
  • Baclofen